Longeveron (LGVN) Operating Income (2020 - 2026)
Longeveron (LGVN) posted quarterly Operating Income of -$4.8 million for Q1 2026, up 7.84% year-over-year from -$4.4 million in Q1 2025, and up 11.56% quarter-over-quarter from -$5.4 million in Q4 2025.
Longeveron (LGVN) Operating Income (2020 - 2026) Analysis & Trends
Longeveron's Operating Income history runs 7 years deep, the most recent figure standing at -$4.8 million for Q1 2026.
- In Q1 2026, Operating Income rose 7.84% year-over-year to -$4.8 million; the TTM figure through Mar 2026 stood at -$22.9 million (down 29.92% YoY), while the FY2025 annual figure was -$23.3 million, down 40.95% from the prior year.
- Operating Income for Q1 2026 stood at -$4.8 million, up from -$5.4 million in the prior quarter.
- The five-year high for Operating Income was -$3.4 million in Q1 2022, with the low at -$7.3 million in Q3 2025.
- The 5-year median for Operating Income is -$5.2 million (2023), against an average of -$4.9 million.
- The sharpest annual moves came in 2024 and 2025: Operating Income soared 38.73% in 2024, then sank 57.24% in 2025.
- Longeveron's Operating Income stood at -$5.2 million in 2022, then decreased by 3.8% to -$5.4 million in 2023, then gained by 21.31% to -$4.3 million in 2024, then decreased by 26.12% to -$5.4 million in 2025, then climbed by 11.56% to -$4.8 million in 2026.
- Business Quant data shows LGVN's Operating Income at -$4.8 million in Q1 2026, -$5.4 million in Q4 2025, and -$7.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 | -6.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.17 Mn |
| Mar 31, 2026 | -4.78 Mn |
| Dec 31, 2025 | -5.40 Mn |
| Sep 30, 2025 | -7.31 Mn |
| Jun 30, 2025 | -5.40 Mn |
| Mar 31, 2025 | -5.18 Mn |
| Dec 31, 2024 | -4.28 Mn |
| Sep 30, 2024 | -4.65 Mn |
| Jun 30, 2024 | -3.50 Mn |
| Mar 31, 2024 | -4.09 Mn |
| Dec 31, 2023 | -5.44 Mn |
| Sep 30, 2023 | -5.16 Mn |
| Jun 30, 2023 | -5.71 Mn |
| Mar 31, 2023 | -4.72 Mn |
| Dec 31, 2022 | -5.24 Mn |
| Sep 30, 2022 | -5.19 Mn |
| Jun 30, 2022 | -4.22 Mn |
| Mar 31, 2022 | -3.39 Mn |
| Dec 31, 2021 | -4.03 Mn |
| Sep 30, 2021 | -4.91 Mn |